How big is iTeos Therapeutics, Inc.?

As of Jun 18, iTeos Therapeutics, Inc. has a market capitalization of 383.50 million, with net sales of 35.00 million and a net profit of -130.81 million over the latest four quarters. Shareholder's funds are reported at 590.29 million, and total assets amount to 686.98 million.

As of Jun 18, iTeos Therapeutics, Inc. has a market capitalization of 383.50 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 35.00 million, while the sum of net profit for the same period is -130.81 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 590.29 million, and total assets amount to 686.98 million.

What does iTeos Therapeutics, Inc. do?

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics. It has a market cap of $383.50 million and reported a net profit loss of $35 million as of March 2025.

Overview:<BR>iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated immuno-oncology therapeutics for patients, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -35 Million (Quarterly Results - Mar 2025)<BR>Market-cap: USD 383.50 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.92<BR>Return on Equity: -23.22%<BR>Price to Book: 0.68<BR><BR>Contact Details:<BR>Address: 139 Main Street, CAMBRIDGE MA: 02142<BR>Tel: 1 857 2044583<BR>Fax: 1 302 6555049<BR>Website: https://www.iteostherapeutics.com/

Should I buy, sell or hold iTeos Therapeutics, Inc.?

Who are in the management team of iTeos Therapeutics, Inc.?

As of March 2022, the management team of iTeos Therapeutics, Inc. includes Mr. David Hallal (Independent Chairman), Dr. Michel Detheux (CEO), and several Independent Directors: Dr. Priyanka Belawat, Dr. Detlev Biniszkiewicz, Mr. Aaron Davis, Dr. Derek DiRocco, and Ms. Ann Rhoads. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of iTeos Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. David Hallal, Independent Chairman of the Board<BR>- Dr. Michel Detheux, Chief Executive Officer and Director<BR>- Dr. Priyanka Belawat, Independent Director<BR>- Dr. Detlev Biniszkiewicz, Independent Director<BR>- Mr. Aaron Davis, Independent Director<BR>- Dr. Derek DiRocco, Independent Director<BR>- Ms. Ann Rhoads, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is iTeos Therapeutics, Inc. overvalued or undervalued?

As of August 8, 2024, iTeos Therapeutics, Inc. is rated as "risky" and overvalued, with key financial metrics indicating distress, including a troubling -23.22% ROE and a 1-month return of 18.11%, despite a 31.69% decline over the past year.

As of 8 August 2024, iTeos Therapeutics, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of 0.69, an EV to EBIT of 0.85, and an EV to EBITDA of 0.86, all indicating significant financial distress. The company's ROE stands at a troubling -23.22%, reflecting ongoing losses.<BR><BR>In comparison to its peers, iTeos Therapeutics has a less favorable valuation with an EV to EBITDA of 0.8967, while Avidity Biosciences, Inc. shows a much worse EV to EBITDA of -5.0262, and Janux Therapeutics, Inc. has an EV to EBITDA of -3.1688. The recent stock performance shows a 1-month return of 18.11%, significantly outperforming the S&P 500's 3.83% return, but the longer-term view reveals a decline of 31.69% over the past year, reinforcing the notion that the stock is currently overvalued.

Is iTeos Therapeutics, Inc. technically bullish or bearish?

As of June 25, 2025, iTeos Therapeutics, Inc. shows a mildly bullish trend with positive MACD signals and daily moving averages, despite short-term weakness indicated by the RSI, while underperforming the S&P 500 over the past 1, 3, and 5 years.

As of 25 June 2025, the technical trend for iTeos Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. However, the weekly RSI is bearish, suggesting some weakness in the short term. The daily moving averages are bullish, supporting the overall positive trend. <BR><BR>In terms of multi-period returns, the stock has underperformed the S&P 500 over the 1-year, 3-year, and 5-year periods, with returns of -40.82%, -55.48%, and -65.72% respectively, compared to the S&P 500's gains of 17.14%, 70.41%, and 96.61%. <BR><BR>Overall, the current technical stance is mildly bullish, driven primarily by the bullish signals from the MACD and daily moving averages, despite some bearish indicators in the RSI and KST.